Verve Therapeutics, Inc. financial data

Symbol
VERV on Nasdaq
Industry
Pharmaceutical Preparations
Location
201 Brookline Avenue, Suite 601, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.64 K % +4.38%
Debt-to-equity 27.4 % +28.5%
Return On Equity -37.4 % +0.77%
Return On Assets -29.3 % +5.51%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 84 M shares +35.8%
Common Stock, Shares, Outstanding 83.8 M shares +35.5%
Entity Public Float 940 M USD -99.8%
Common Stock, Value, Issued 84 K USD +35.5%
Weighted Average Number of Shares Outstanding, Basic 83.1 M shares +34.5%
Weighted Average Number of Shares Outstanding, Diluted 83.1 M shares +34.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 186 M USD +21.9%
General and Administrative Expense 51.5 M USD +20.9%
Operating Income (Loss) -222 M USD -15.5%
Nonoperating Income (Expense) 25.3 M USD +96.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -196 M USD +6.44%
Income Tax Expense (Benefit) 381 K USD
Net Income (Loss) Attributable to Parent -197 M USD -9.84%
Earnings Per Share, Basic -2.87 USD/shares +8.31%
Earnings Per Share, Diluted -2.87 USD/shares +8.31%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 144 M USD +72.2%
Marketable Securities, Current 462 M USD +8.76%
Cash, Cash Equivalents, and Short-term Investments 606 M USD
Assets, Current 620 M USD +19.8%
Property, Plant and Equipment, Net 21 M USD -0.14%
Operating Lease, Right-of-Use Asset 83.5 M USD -7.2%
Other Assets, Noncurrent 2.71 M USD +282%
Assets 732 M USD +15.4%
Accounts Payable, Current 3.05 M USD -9.58%
Accrued Liabilities, Current 16.6 M USD -12.9%
Liabilities, Current 31.3 M USD -6.73%
Operating Lease, Liability, Noncurrent 63.5 M USD -7.94%
Other Liabilities, Noncurrent 165 K USD -36.5%
Liabilities 149 M USD +19.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -500 K USD -111%
Retained Earnings (Accumulated Deficit) -593 M USD -49.7%
Stockholders' Equity Attributable to Parent 583 M USD +14.4%
Liabilities and Equity 732 M USD +15.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.1 M USD +12.2%
Net Cash Provided by (Used in) Financing Activities 22.7 M USD +1016%
Net Cash Provided by (Used in) Investing Activities -41.6 M USD -370%
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 83.8 M shares +35.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -62 M USD -95.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 149 M USD +68.2%
Deferred Tax Assets, Valuation Allowance 172 M USD +57%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 197 M USD +45.1%
Operating Lease, Liability 73.7 M USD -8.04%
Depreciation 5.96 M USD +74.4%
Payments to Acquire Property, Plant, and Equipment 433 K USD -87.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -197 M USD -10.3%
Lessee, Operating Lease, Liability, to be Paid 103 M USD -10.7%
Property, Plant and Equipment, Gross 33 M USD +21.6%
Operating Lease, Liability, Current 10.2 M USD -8.62%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.2 M USD +6.13%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.9 M USD +22.2%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29.7 M USD -16.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11.5 M USD +6.13%
Deferred Tax Assets, Operating Loss Carryforwards 51.3 M USD +17.2%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 0 USD
Current Income Tax Expense (Benefit) 275 K USD +419%
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.9 M USD +6.13%
Operating Lease, Payments 2.64 M USD -16.1%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 275 K USD +419%
Current Federal Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 37.4 M USD +42.3%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%